insights_auto
Why is 4142 down ६.६२%?
Dive Deeperchevron_right
4142:TPE
Adimmune Corp
NT$ १४.८०
arrow_downward
-६.६२%(-१.०५) 1D
नोभेम्बर २०, १३:३०:०९ GMT+८ · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
NT$ १५.७५
High
NT$ १५.७५
Low
NT$ १४.८०
Mkt. cap
६.३६ अरब
Avg. vol.
११.२६ लाख
Volume
१६.२९ लाख
P/E ratio
८५.७६
52-wk high
NT$ २१.५०
52-wk low
NT$ १४.८०
EPS
NT$ ०.१७
Shares outstanding
२३.५३ करोड
No. of employees
५६४
Open
NT$ १५.७५
High
NT$ १५.७५
Low
NT$ १४.८०
Mkt. cap
६.३६ अरब
Avg. vol.
११.२६ लाख
Volume
१६.२९ लाख
P/E ratio
८५.७६
52-wk high
NT$ २१.५०
52-wk low
NT$ १४.८०
EPS
NT$ ०.१७
Shares outstanding
२३.५३ करोड
No. of employees
५६४
News stories
From web sources and news partners
marketscreener.com
·
१ घण्टा पहिले
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
३४ मिनेट पहिले
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
24/7 Wall St.
·
३४ मिनेट पहिले
The S&P 500 Just Had Its Biggest Reversal Since March 2020
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp